Peptide having cancer selective translocation function and use thereof
US-2015165060-A1 · Jun 18, 2015 · US
Anticancer peptide for inhibiting proliferation of cancer stem cells and use thereof
US9993519B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9993519-B2 |
| Application number | US-201615113823-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 3, 2016 |
| Priority date | Mar 26, 2015 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-κB which is overexpressed specifically in cancer stem cells present in tumors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating breast cancer, the method comprising: administering a peptide to a patient with breast cancer, wherein the peptide is represented by an amino acid sequence of SEQ ID NOs: 2 or 3. 2. The method of claim 1 , wherein the peptide inhibits the activity of NF-κB in breast cancer cells or breast cancer stem cells. 3. The method of claim 1 , wherein the peptide inhibits the proliferation of breast cancer cells or breast cancer stem cells. 4. The method of claim 1 , wherein the peptide induces the apoptosis of breast cancer cells or breast cancer stem cells. 5. The method of claim 2 , wherein the breast cancer stem cells are included in breast cancer cells derived from a metastatic breast tumor. 6. The method of claim 1 , wherein the administering is by oral, injection, or local transplantation. 7. The method of claim 6 , wherein the local transplantation comprises administering a gelling agent that comprises a synthetic polymer or a natural polymer. 8. The method of claim 7 , wherein the synthetic polymer is any one selected from the group consisting of polylacticglycolic acid, and poloxamer. 9. The method of claim 7 , wherein the natural polymer is any one selected from the group consisting of collagen, chondroitin sulfate, and chitosan. 10. The method of claim 3 , wherein the breast cancer stem cells are included in breast cancer cells derived from a metastatic breast tumor. 11. The method of claim 4 , wherein the breast cancer stem cells are included in breast cancer cells derived from a metastatic breast tumor.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates · CPC title
- A61K38/10Primary
Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title
- A61K38/1729Primary
Cationic antimicrobial peptides, e.g. defensins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9993519B2 cover?
- The present invention relates to an anticancer composition comprising a peptide that inhibits the proliferation of cancer stem cells present in tumor tissue and that induces apoptosis of such cancer stem cells, and more particularly, to an anticancer peptide that inhibits the activity of NF-κB which is overexpressed specifically in cancer stem cells present in tumors.
- Who is the assignee on this patent?
- Seoul Nat Univ R&Db Foundation, Nano Intelligent Biomedical Eng Corporation Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K38/10. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).